Krska
Rudolf Krska, Tulln AT
Patent application number | Description | Published |
---|---|---|
20090068706 | Production of Highly Isotopically Labelled, Secondary, Microbial Metabolic Products, and Corresponding Metabolic Products - The invention relates to a method for producing isotopically labelled secondary metabolic products of fungi or bacteria in a liquid synthetic culture medium. According to said method, the synthesis is carried out by immobilizing the fungi or bacteria on an inert carrier, adding a liquid synthetic culture medium in which essentially all of the carbon atoms, nitrogen atoms and/or sulphur atoms are replaced by stable isotopes. | 03-12-2009 |
20100258494 | Packing Material for a Micro-Adsorption Column for Drying and/or Purification of Dissolved Organic or Biological Analytes and Micro-Adsorption Column and use thereof - The invention relates to a packing material for a micro-adsorption column for drying and/or purification of dissolved organic or biological analytes, such as toxins, antibiotics, vitamins, hormones, pesticides and similar, containing at least one drying agent which contains magnesium sulphate and at least one further drying agent selected from the group comprising aluminium oxide, calcium chloride, calcium hydride, calcium oxide, calcium sulphate, potassium hydride, silica gel, copper sulphate, magnesium oxide, magnesium perchlorate, molecular sieves, sodium hydroxide, phosphorus pentoxide, sulphuric acid on silica, phosphorus pentoxide on silica and 0.5 to 90 wt. % of a naturally-occurring or synthetic support with large internal surface such as zeolite, diatomic earths, bentonite, silicon dioxide or similar. The invention further relates to a micro-adsorption column packed with the above and use thereof. | 10-14-2010 |
Shane W. Krska, New Providence, NJ US
Patent application number | Description | Published |
---|---|---|
20130331379 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST - The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof. | 12-12-2013 |
20150274755 | COMPOUND DIVERSIFICATION USING LATE STAGE FUNCTIONALIZATION - The present invention relates to methods for generating limited chemical diversity for biologically relevant lead molecules by late state functionalization, separation, and post-functionalization modification. The methods optionally include one or more screening steps. Traditional drug development has relied on the synthesis of individual compounds or the generation of large chemical libraries, but these methods have generally been fairly inefficient in obtaining drug products. | 10-01-2015 |
Shane W. Krska, Rahway,, NJ US
Patent application number | Description | Published |
---|---|---|
20150274755 | COMPOUND DIVERSIFICATION USING LATE STAGE FUNCTIONALIZATION - The present invention relates to methods for generating limited chemical diversity for biologically relevant lead molecules by late state functionalization, separation, and post-functionalization modification. The methods optionally include one or more screening steps. Traditional drug development has relied on the synthesis of individual compounds or the generation of large chemical libraries, but these methods have generally been fairly inefficient in obtaining drug products. | 10-01-2015 |